PT  - JOURNAL ARTICLE
AU  - Richelson, E
AU  - Nelson, A
AU  - Neeper, R
TI  - Binding of benzodiazepines and some major metabolites at their sites in normal human frontal cortex in vitro.
DP  - 1991 Mar 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 897--901
VI  - 256
IP  - 3
4099  - http://jpet.aspetjournals.org/content/256/3/897.short
4100  - http://jpet.aspetjournals.org/content/256/3/897.full
SO  - J Pharmacol Exp Ther1991 Mar 01; 256
AB  - Using [3H]flunitrazepam in radioligand binding assays, we determined equilibrium dissociation constants (Kd's) at 37 degrees C for 22 benzodiazepines (15 parent compounds and 7 major metabolites) at benzodiazepine binding sites in human frontal cortex. This list included several compounds never studied before at human receptors. Although dissociation was too rapid to measure reliably at this temperature, the Kd's for flunitrazepam were not significantly different when either rapid filtration or centrifugation was used to separate the bound from free radioligand. The most potent compound was triazolam (Kd = 0.54 nM); the least potent, chlordiazepoxide (Kd = 684 nM). The Kd's were significantly lower (about 3- to 7-fold) for several compounds tested at an equilibrium temperature of 0 degrees C compared to those obtained at 37 degrees C. There was a strong correlation for 15 compounds for the log Kd at rat brain receptors (data obtained from the literature) vs. the log Kd for human brain. In addition, the log Kd's of the various benzodiazepines for their receptor were significantly correlated with the log of their minimum daily dosages used to treat patients. Many of the benzodiazepines have clinically important active metabolites that have higher affinity for benzodiazepine binding sites in human brain than their parent compounds. Such data have important implications in the clinical use of these compounds.